Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 9/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186644 | 0.92 | PDE4B (0.51) | PDE4BCYP19A1CNR1CNR2PDE4A | |
| SCHEMBL700719 | 0.87 | CNR1 (0.58) | PDE4BCYP19A1CNR1CNR2 | |
| SCHEMBL5484151 | 0.86 | PDE4B (0.54) | PDE4BCYP19A1CNR1CNR2PDE4A | |
| SCHEMBL974512 | 0.86 | PDE4B (0.54) | PDE4BCYP19A1CNR1CNR2PDE4A | |
| SCHEMBL4689858 | 0.85 | CNR1 (0.52) | PDE4BCYP19A1CNR1PDE4APDE4C | |
| SCHEMBL5463050 | 0.85 | PDE4B (0.47) | PDE4BCYP19A1CNR1CNR2PDE4A | |
| SCHEMBL4695480 | 0.85 | PDE4B (0.53) | PDE4BCYP19A1CNR1CNR2PDE4A | |
| SCHEMBL4816797 | 0.85 | PDE4B (0.53) | PDE4BCYP19A1CNR1CNR2PDE4A | |
| SCHEMBL4692303 | 0.85 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL4184217 | 0.84 | CNR1 (0.53) | PDE4BCYP19A1CNR1PDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874779-A1 | ACYLAMINOBICYCLIC HETEROMATIC COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007060525-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060525-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
| WO-2006111849-A1 | ACYLAMINOBICYCLIC HETEROMATIC COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | CNR2, CNR1, GPR18 | PDE4B 2817/4885CYP19A1 394/4885CNR1 2/4885 |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | PDE4B 1438/4885CYP19A1 1349/4885CNR1 2/4885 |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | CNR2, CNR1, GPR18 | PDE4B 1438/4885CYP19A1 1349/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.